TAMPA, FL - (BUSINESS WIRE) — March 16, 2005 — Nanobac Life Sciences, Inc. (OTCBB: NNBP) (“Nanobac” or “the Company”) informs that researchers have described a relationship between Nanobacteria and urological disorders such as prostatitis, kidney stones, and Polycystic Kidney Disease (PKD). Until these studies, no single infection, viral or bacterial had been indicated that could have promoted these disease processes. Because of the debilitating nature of these urological diseases, and the Company’s belief that Nanobacteria might play a key role in their development, Nanobac has focused its efforts on investigating the relationship between Nanobacteria and these diseases. This release is intended to summarize what has been determined thus far, and what remains to be done.
A recent observational study of prostatitis patients, lead by Daniel A. Shoskes, M.D., of Cleveland Clinic Florida, demonstrated a significant improvement in the symptoms of chronic prostatitis/chronic pelvic pain syndrome for those patients who took 3 months of Nanobac’s comET nanobiotic regimen, a patented therapeutic method comprised of a nutriceutical (Nanobac Oral Supplement, Nanobac Sciences, Tampa, FL), EDTA (Calcium Disodium EDTA Suppository (Nanobac Sciences, Tampa, FL) and tetracycline. The treated group of fifteen patients had prostatic stones and longstanding Chronic Pelvic Pain Syndrome (CPPS) symptoms unresponsive to multiple prior conventional therapies. The treatment is designed to eliminate stone forming Nanobacteria and the study found that 80% had a significant improvement in symptoms after 3 months. Two patients who had been on complete medical disability have returned to work.
The Nanobac Oral Supplement and Calcium Disodium EDTA components of the comET regimen are available through Nanobac Sciences.
Kidney stones can be debilitating and affect 20 million Americans and recur in 50% of patients within 5 years. Several studies conducted by prominent medical researchers worldwide have collectively shown Nanobacteria as a probable cause of kidney stone formation. Depending on the patient population, researchers have reported that 62% to 97% of kidney stones have Nanobacteria. What is more remarkable is that the presence of Nanobacteria is independent of the stone type. Since Nanobacteria create calcific deposits and are physically present in the kidney stones, they are therefore thought to be the initiator of kidney stone formation. Neva Ciftcioglu, Director of Science at Nanobac Life Sciences, Inc, and a team of NASA scientists used multiple techniques to determine that Nanobacteria infection multiplies faster in space flight simulated conditions than on Earth. Astronauts are at an increased risk for kidney stones on long duration missions. This novel concept opens the door for new diagnostic and therapeutic techniques addressing nanobacterial infection in kidney stones.
Polycystic kidney disease
(PKD) is a genetic disorder characterized by the growth of numerous cysts in the kidneys. The cysts are filled with fluid. PKD cysts can slowly replace much of the mass of the kidneys, reducing kidney function and leading to kidney failure. Studies have shown that in PKD patients up to 100% of kidney cyst fluids and urine were positive for Nanobacteria. Because Nanobacteria are present in PKD patients, it is reasonable to ask if the current diagnostic tools and therapeutic treatments available for PKD are sufficient to address the problem. Nanobac plans to initiate research trials that will evaluate the link between Nanobacteria and PKD. We are positioned to provide novel diagnostics and research potential nanobacterial treatments for this disease.
Nanobac Life Sciences, Inc. is dedicated to improving people’s health through the detection and eradication of Nanobacterium sanguineum (Nanobacteria). The Company’s pioneering research is establishing the pathogenic role of Nanobacteria in calcification, particularly in coronary artery heart disease and vascular disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2™ ELISA assays to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop the first FDA approved therapeutic to treat nanobacterial infection. The Company currently markets a patented nanobiotic regimen. For further information concerning our nanobiotic, please visit http://www.nanobacsciences.com.
Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as “believes,” “anticipates,” “intends,” “plans,” “expects,” and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.